Novel IKKβ inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method

被引:7
作者
Huang, Jing-Jie [1 ,2 ]
Wu, Xiao-Wen [1 ,2 ]
Jia, Jian-Min [1 ,2 ]
Guo, Xiao-Ke [1 ,2 ]
Xue, Xin [1 ,2 ]
Jiang, Zheng-Yu [1 ,2 ]
Zhang, Sheng-Lie [1 ,2 ]
Zhang, Xiao-Jin [2 ,4 ]
Sun, Hao-Peng [2 ,3 ]
You, Qi-Dong [1 ,2 ,3 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China
[3] China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China
[4] China Pharmaceut Univ, Dept Organ Chem, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
I kappa B kinase beta (IKK beta) inhibitor; Pharmacophore; Molecular docking; Virtual screening; Biological test; KAPPA-B-KINASE; HOMOLOGY MODEL; CANCER; POTENT; INFLAMMATION; IDENTIFICATION; ACTIVATION; DOCKING; GLIDE;
D O I
10.1016/j.ejmech.2013.01.045
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
I kappa B kinase beta (IKK beta), an attractive anti-inflammation and anti-cancer target, plays a crucial role in the activation of NF-kappa B signalling pathway. To identify novel IKK beta inhibitors, we combined structure-based and ligand-based methods based on the co-crystal structure of IKK beta. According to the chemical similarity, 162 reported IKK beta inhibitors were divided into five classes. For each class, a 3D pharmacophore model was established based on the binding conformations of the compounds. The validated models were further used in virtual screening. Twelve drugable compounds were retained for biological test, resulting in two novel inhibitors with IC50 values lower than 10 mu M. Compared to other models, our method considers the crystal structure of IKK beta for the first time. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:269 / 278
页数:10
相关论文
共 46 条
  • [1] NF-κB activation in cancer:: a challenge for ubiquitination- and proteasome-based therapeutic approach
    Amit, S
    Ben-Neriah, Y
    [J]. SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) : 15 - 28
  • [2] Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors
    Baxter, A
    Brough, S
    Cooper, A
    Floettmann, E
    Foster, S
    Harding, C
    Kettle, J
    McInally, T
    Martin, C
    Mobbs, M
    Needham, M
    Newham, P
    Paine, S
    St-Gallay, S
    Salter, S
    Unitt, J
    Xue, YF
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (11) : 2817 - 2822
  • [3] Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors
    Beaulieu, Francis
    Ouellet, Carl
    Ruediger, Edward H.
    Belema, Makonen
    Qiu, Yuping
    Yang, Xuejie
    Banville, Jacques
    Burke, James R.
    Gregor, Kurt R.
    MacMaster, John F.
    Martel, Alain
    McIntyre, Kim W.
    Pattoli, Mark A.
    Zusi, F. Christopher
    Vyas, Dolatrai
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (05) : 1233 - 1237
  • [4] Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors
    Belema, Makonen
    Bunker, Amy
    Nguyen, Van N.
    Beaulieu, Francis
    Ouellet, Carl
    Qu, Yuping
    Zhang, Yunhui
    Martel, Alain
    Burke, James R.
    Mclntyre, Kim W.
    Pattoli, Mark A.
    Daloisio, Connie
    Gillooly, Kathleen M.
    Clarke, Wendy J.
    Brassil, Patrick J.
    Zusi, F. Chris
    Vyasa, Dolatrai M.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (15) : 4284 - 4289
  • [5] Inflammation meets cancer, with NF-κB as the matchmaker
    Ben-Neriah, Yinon
    Karin, Michael
    [J]. NATURE IMMUNOLOGY, 2011, 12 (08) : 715 - 723
  • [6] EB1627:: a soluble prodrug of the potent anticancer cyanoguanidine CHS828
    Binderup, E
    Björkling, F
    Hjarnaa, PV
    Latini, S
    Baltzer, B
    Carlsen, M
    Binderup, L
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (10) : 2491 - 2494
  • [7] A novel series of potent and selective IKK2 inhibitors
    Bingham, AH
    Davenport, RJ
    Gowers, L
    Knight, RL
    Lowe, C
    Owen, DA
    Parry, DM
    Pitt, WR
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) : 409 - 412
  • [8] Synthesis and structure-activity relationship of aminopyrimidine IKK2 inhibitors
    Bingham, Alistair H.
    Davenport, Richard J.
    Fosbeary, Richard
    Gowers, Lewis
    Knight, Roland L.
    Lowe, Christopher
    Owen, David A.
    Parry, David M.
    Pitt, Will R.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (12) : 3622 - 3627
  • [9] Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides
    Bonafoux, D
    Bonar, S
    Christine, L
    Clare, M
    Donnelly, A
    Guzova, J
    Kishore, N
    Lennon, P
    Libby, A
    Mathialagan, S
    McGhee, W
    Rouw, S
    Sommers, C
    Tollefson, M
    Tripp, C
    Weier, R
    Wolfson, S
    Min, Y
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (11) : 2870 - 2875
  • [10] Drug-like Bioactive Structures and Conformational Coverage with the LigPrep/ConfGen Suite: Comparison to Programs MOE and Catalyst
    Chen, I-Jen
    Foloppe, Nicolas
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2010, 50 (05) : 822 - 839